FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3209043235> ?p ?o ?g. }

• W3209043235 endingPage "1033" @default.
• W3209043235 startingPage "1029" @default.
• W3209043235 abstract "The term super responders defines a subset of patients with moderate-to-severe psoriasis that present a rapid and higher rate of response to biological treatments in comparison to the general population. Little scientific evidence to explain the behavior and clinical characteristics of these psoriatic patients has been published thus far. Its characterization could be important to improve therapeutic optimization and to identify the profile of patients that will respond efficiently to biological treatments.The main objective of this study was to evaluate and characterize the proportion of super-responder patients (who achieved PASI = 0 at week 12 and 24) in a total of 87 patients with moderate-to-severe psoriasis treated with guselkumab. Also, our intent was to analyze and evaluate differences in response to guselkumab in absolute PASI, PASI 75, PASI 90, PASI 100, BSA, VAS pruritus, and DLQI between groups.A total of 14 out of 87 patients treated with guselkumab were characterized as SR. No differences in demographic characteristics were found. The percentage of patients reaching PASI 75, PASI 90, and PASI 100 were numerically greater for SR than N-SR at week 12, 24, 36, and 52. These differences were more pronounced for PASI 100 > PASI 90 > PASI 75. SR performed better and faster to guselkumab treatment as assessed by absolute PASI, BSA, VAS pruritus, and DLQI. Statistically significant differences were found in absolute PASI, BSA, VAS pruritus, and DLQI between groups along the 52 weeks of study. No differences in drug survival were found between groups (P = 0.3326).Our study demonstrated for the first time, in a real clinical practice setting, the presence of a subpopulation of patients that super respond to guselkumab at week 12 and 24 and maintain this efficacy for 52 weeks. Further research must be performed to identify basal specific characteristics of this SR population." @default.
• W3209043235 created "2021-11-08" @default.
• W3209043235 creator A5016362733 @default.
• W3209043235 creator A5018673082 @default.
• W3209043235 creator A5044900789 @default.
• W3209043235 creator A5057595041 @default.
• W3209043235 creator A5080180028 @default.
• W3209043235 date "2021-11-03" @default.
• W3209043235 modified "2023-10-18" @default.
• W3209043235 title "Super responders to guselkumab treatment in moderate‐to‐severe psoriasis: a real clinical practice pilot series" @default.
• W3209043235 cites W2106686862 @default.
• W3209043235 cites W2124686679 @default.
• W3209043235 cites W2570141807 @default.
• W3209043235 cites W2697574135 @default.
• W3209043235 cites W2943923722 @default.
• W3209043235 cites W2955042287 @default.
• W3209043235 cites W2991659810 @default.
• W3209043235 cites W3013434472 @default.
• W3209043235 cites W3108752263 @default.
• W3209043235 cites W3123986339 @default.
• W3209043235 cites W4211077900 @default.
• W3209043235 doi "https://doi.org/10.1111/ijd.15784" @default.
• W3209043235 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34731493" @default.
• W3209043235 hasPublicationYear "2021" @default.
• W3209043235 type Work @default.
• W3209043235 sameAs 3209043235 @default.
• W3209043235 citedByCount "8" @default.
• W3209043235 countsByYear W32090432352022 @default.
• W3209043235 countsByYear W32090432352023 @default.
• W3209043235 crossrefType "journal-article" @default.
• W3209043235 hasAuthorship W3209043235A5016362733 @default.
• W3209043235 hasAuthorship W3209043235A5018673082 @default.
• W3209043235 hasAuthorship W3209043235A5044900789 @default.
• W3209043235 hasAuthorship W3209043235A5057595041 @default.
• W3209043235 hasAuthorship W3209043235A5080180028 @default.
• W3209043235 hasConcept C126322002 @default.
• W3209043235 hasConcept C141071460 @default.
• W3209043235 hasConcept C16005928 @default.
• W3209043235 hasConcept C2776173921 @default.
• W3209043235 hasConcept C2777011040 @default.
• W3209043235 hasConcept C2780564577 @default.
• W3209043235 hasConcept C2908647359 @default.
• W3209043235 hasConcept C30036603 @default.
• W3209043235 hasConcept C71924100 @default.
• W3209043235 hasConcept C90924648 @default.
• W3209043235 hasConcept C99454951 @default.
• W3209043235 hasConceptScore W3209043235C126322002 @default.
• W3209043235 hasConceptScore W3209043235C141071460 @default.
• W3209043235 hasConceptScore W3209043235C16005928 @default.
• W3209043235 hasConceptScore W3209043235C2776173921 @default.
• W3209043235 hasConceptScore W3209043235C2777011040 @default.
• W3209043235 hasConceptScore W3209043235C2780564577 @default.
• W3209043235 hasConceptScore W3209043235C2908647359 @default.
• W3209043235 hasConceptScore W3209043235C30036603 @default.
• W3209043235 hasConceptScore W3209043235C71924100 @default.
• W3209043235 hasConceptScore W3209043235C90924648 @default.
• W3209043235 hasConceptScore W3209043235C99454951 @default.
• W3209043235 hasIssue "8" @default.
• W3209043235 hasLocation W32090432351 @default.
• W3209043235 hasLocation W32090432352 @default.
• W3209043235 hasOpenAccess W3209043235 @default.
• W3209043235 hasPrimaryLocation W32090432351 @default.
• W3209043235 hasRelatedWork W1798097943 @default.
• W3209043235 hasRelatedWork W1892203605 @default.
• W3209043235 hasRelatedWork W2380806412 @default.
• W3209043235 hasRelatedWork W2415983218 @default.
• W3209043235 hasRelatedWork W2477169218 @default.
• W3209043235 hasRelatedWork W2545526290 @default.
• W3209043235 hasRelatedWork W2709458184 @default.
• W3209043235 hasRelatedWork W2766413417 @default.
• W3209043235 hasRelatedWork W2767862884 @default.
• W3209043235 hasRelatedWork W2896346672 @default.
• W3209043235 hasVolume "61" @default.
• W3209043235 isParatext "false" @default.
• W3209043235 isRetracted "false" @default.
• W3209043235 magId "3209043235" @default.
• W3209043235 workType "article" @default.